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exposure to cognitively stimulating activities on cognitive performance may be weaker in carriers of the methionine allele [16] . Thus, the methionine allele may be a prognostic biomarker for predicting cognitive decline due to AD. That being said, extensive study in over 30 populations (Caucasian, Asian, African and mixed) has failed to demonstrate a replicable association of BDNF genetic variants with altered AD risk (www.Alzgene.org [17] ).
Studies using rodent models have shown that a reduction in BDNF levels may precede the appearance of amyloid plaque pathology [18] . Reduced BDNF levels have been associated with altered synaptic plasticity [19] [20] [21] , increased cortical amyloid plaque numbers, and reduced noradrenergic innervation of the hippocampus, frontal cortex, and cerebellum [22] of animal models, effects that can be reversed with BDNF treatment [23] [24] [25] [26] [27] .
Taken together, data from animal and human studies strongly support an important neuroprotective effect of BDNF and that an imbalance in BDNF signalling may be an early event in AD pathogenesis. It follows that modulation of BDNF secretion could be critical to this process. In this regard, previous studies using rodent models have reported a feed forward loop between BDNF and the noradrenergic system, whereby noradrenaline (norepinephrine) induces astrocytic and neuronal BDNF secretion, which in turn stimulates noradrenergic signalling as part of an anti-inflammatory mechanism [28] [29] [30] [31] [32] . In support of this, reduced noradrenaline levels have also been reported in aged and AD brains and it has been hypothesised that increasing noradrenergic signalling in the brain could halt the progression of neurodegeneration and cognitive decline (reviewed in [33] ). Noradrenaline is synthesised from dopamine, a reaction catalysed by dopamine beta-hydroxylase (DBH) and is an anti-inflammatory agent that can attenuate the cortical inflammatory response to the Aβ 42 peptide [34] . Thus deregulation of DBHmediated synthesis of noradrenaline could have downstream effects on BDNF secretion.
An additional factor in BDNF secretion is the intracellular sorting of BDNF to the secretory pathway, which is regulated by binding of the BDNF pro-domain to the luminal domain of Sortilin [35] . This interaction prevents BDNF degradation, targets BDNF to the secretory pathway [36] and facilitates the release of mature BDNF [37] .
The aims of this first study of Stage 2 of the Epistasis Project (the results of Stage 1 [38] [39] [40] [41] [42] [43] [44] are summarised in Table 1 ), were to further evaluate the contribution of genetic variation at the BDNF locus to AD risk in a large case-control dataset (n=8,136) and determine whether the association could be masked by genetic epistasis between BDNF variants and sex, age, APOE ε4 status and variants at loci encoding proteins that control BDNF secretion (DBH and Sortilin).
Materials and Methods

Study population
DNA samples were collected from individuals of Caucasian European descent by seven research centres within two geographical regions namely, Northern Europe (Bristol, Nottingham, OPTIMA and Rotterdam) and Spain (Madrid, Oviedo and Santander). All AD cases were diagnosed "definite" or "probable" by CERAD or NINCDS-ADRDA criteria. AD cases were sporadic, i.e. possible autosomal dominant cases were excluded, based on family history. The cohorts in Stage 1 of the Epistasis Project were described in [38] . In this Stage 2, the Bonn cohort was replaced by that from Madrid, giving a better overall balance between Northern Europe and Spain. The Madrid cohort fulfilled our criteria of an all-Caucasian population drawn from a narrow geographical region.
The demographics of each sample collection are shown in Table 2 . Research ethics approval was obtained by each of the participating groups. Written informed consent was given for donation of blood samples from all participants, or their legal representatives.
Polymorphism selection
We downloaded Caucasian European (CEU) population data from the HaploView platform (release 27) using gene coordinates (gene +/-10kbp flanking regions) extracted from the UCSC MySQL server (hg18) at https://genome.ucsc.edu/.
Polymorphisms with a genotype rate <50%, and that were in Hardy-Weinberg equilibrium (p<0.001) and with a minor allele frequency (MAF) <5% were removed.
The remaining polymorphisms were introduced into the tagger function in HaploView.
A tagging threshold of r 2 >0.8 and log odds (LOD) score>3.0 was used. The "Aggressive Tagging" approach was implemented, which allows a haplotype of up to three polymorphisms to be used as a proxy. We identified 34 polymorphisms (5 in BDNF, 23 in DBH and 6 in SORT1) that have a minor allele frequency >5% in Caucasian Europeans and that cover 80% of the variation in these genes ( Table 3) . Due to the considerable variation in DBH, coverage of this gene was restricted to rs1611115, which has previously been associated with increased AD risk in men aged <75 [39] and is responsible for 30-50% of the considerable variation in DBH activity [46] [47] [48] [49] [50] [51] [52] [53] . The 12 polymorphisms were taken forward for genotyping.
Genotyping and imputation
Genotyping for all centres except Rotterdam (below) was performed by LGC I version 3 reference panel, positive strand) as a reference. The reliability of imputation was estimated for each imputed SNP with the ratio of expected and observed dosage variance (O/E ratio). Only samples with high-quality extracted DNA were genotyped. In order to allow analysis alongside the genotyped cohorts, the imputed probabilities from Rotterdam were converted to genotypes such that a value of 0 was coded as homozygote for allele 2, a value of 1 was coded as heterozygote and a value of 2 was coded as homozygote for allele 1. It should be noted that a dosage of 1 could be heterozygote, but it could also mean that person has a 0.5 probability of being homozygote for allele 1 and a 0.5 probability of being homozygote for allele 2. That being said, it is commonplace in genetics to round these values to 0/1/2 with the implied corresponding genotypes.
The supplementary table shows the genotype counts and allele frequencies as well as genotyping rate for all individual centres. The genotyping rate for each polymorphism ranged from 0.99 to 1.00 in the total dataset. All genotypes were confirmed to be in Hardy-Weinberg equilibrium (α=0.001) in controls from all individual centres. APOE ε4 genotypes were determined according to the genotypes at rs429358 and rs7412. Tests for pair-wise intragenic linkage disequlibrium for the 5 BDNF polymorphisms and the 6 SORT1 polymorphisms were consistent with the Haploview data (r<0.8) with the exception of rs6265 and rs11030104 in BDNF (r 2 =0.9) and rs2228604 and rs10745354 in SORT1 (r 2 =1.0). The high degree of co-inheritance of these pairs was replicated in both the Northern European and Spanish controls. The polymorphisms rs11030104 (BDNF) and rs10745354 (SORT1) were therefore removed from the study as they provided no further information.
Statistical analyses
All analyses were performed in R version 3.5.0 [54] . The relative risk (odds ratios and 95% confidence intervals; CI) for AD was calculated for each of the 10 polymorphisms brought forward for analysis using a general linear model for dominant and recessive inheritance models controlling for age-at-extraction, sex, APOE ε4 allele and individual centre. The Akaike Information Criterion (AIC) was used to compare goodness-of-fit, with smaller values of AIC corresponding to preferable models. The statistical power for each sample included in the study to detect a significant (α=0.05) association of a polymorphism with a minor allele frequency 0.2 (mean of polymorphisms included in the study) with AD risk ( dataset, analyses were subsequently tested in the Rotterdam subset as the only collection centre with sufficient statistical power to detect an association. Interactions were assessed using the Synergy Factor (SF) described in [55] . Using this method, the SF=actual OR (joint effect of two factors) / predicted OR (product of the OR for each factor alone). The null hypothesis states that the actual OR is equal to the predicted OR.
This method assesses interactions on a multiplicative scale rather than an additive scale.
Throughout the study, significance was considered at the α=0.05 level. However, due to the large number of tests performed (n=224 in total), the Bonferroni cut-off (α=0.0002)
can be considered as a more stringent cut-off for significance that minimizes the falsepositive associations reported. Associations that surpass this cut-off are indicated in the text and figures.
Results
Genetic variation at the BDNF locus is associated with increased AD risk
We tested for association of the 4 BDNF polymorphisms with altered AD risk in the total population. The model preferred (lowest AIC) for BDNF1 was the recessive inheritance model, whereas the preferred models for BDNF2-4 were the dominant models. The OR and 95% CI for the preferred models of each polymorphism are plotted in To determine whether interactions between BDNF polymorphisms could explain the contradictory findings for rs6265 (BDNF1) across multiple populations, we sequentially added pair-wise interactions between the 4 BDNF polymorphisms into the model. No interaction between BDNF polymorphisms was associated with altered AD risk (p>0.5).
Women showed increased susceptibility to AD risk-modifying polymorphisms at the BDNF locus
We next tested whether interactions between BDNF polymorphisms and age-atsampling, sex and possession of the APOE ε4 allele could contribute to AD risk. We found no association of the BDNF1*sex interaction with AD risk (SF=0.95, p=0.9).
However, inclusion of BDNF2*sex, BDNF3*sex or BDNF4*sex interactions improved the AIC for the model and the synergy factors (SF) for these interactions are plotted in That being said, these interactions may be of less importance since including them in the models did not improve the AIC. Interactions between other BDNF variants and ε4
were not associated with AD risk (p>0.06) and neither were interactions between any BDNF variant and age (p>0.2).
BDNF and DBH polymorphisms act synergistically to increase AD risk in
Northern European women
We have previously identified an association of the DBH polymorphism, rs1611115, with increased AD risk in men aged <75 [39] in a sample set that overlaps with that included in this study. Therefore, unsurprisingly, when testing for an association of DBH with AD risk in the total population, we found that the DBH polymorphism was associated with increased risk of AD in the total dataset (rs1611115T+ OR=1.12, p=0.04), albeit that the association was not apparent in either of the regional subsets 
SORT1 genetic variation is not associated with AD risk
Finally we tested for an association of SORT1 polymorphisms with AD risk. We found no association in the total, Northern European or Spanish populations (p>0.05). We tested for an association of interactions between the SORT1 polymorphisms and age-atsampling, sex and possession of the APOE ε4 allele with AD risk. We observed an antagonistic interaction between SORT1e (rs1149175 GG) and sex in the Spanish dataset (SORT1e OR=2.2, sex OR=2.1, SF=0.4, p=0.007) and SORT1e was associated with increased AD risk in Spanish men (OR=2.27, p=0.002). That being said, these interactions may be of less importance since including them in the models did not improve the AIC. None of the interactions with the BDNF variants contributed to AD risk in the total or regional subsets (p>0.05).
Discussion
This multi-cohort study of 5,682 controls and 2,454 AD patients (recruited from seven research centres from Northern Europe and Spain) represents a comprehensive exploration of the contribution of epistatic interactions between genes encoding proteins implicated in BDNF secretion and noradrenergic innervation to AD risk. The main finding of this study is the synergistic interaction between BDNF risk-modifying variants (BDNF2-4) and sex (SF=1.3 to 1.5) such that the BDNF-associated risk was observed in women (OR=1.2 to 1.3) but not men (OR=0.9 to 1.0). We also show evidence of a synergistic interaction between the BDNF and DBH loci such that carriers of the minor allele at DBH (rs1611115) who are also homozygous for the minor allele at BDNF1 (rs6265) are at increased risk of AD (SF=2.2) than carriers of either allele alone (BDNF OR=1.1 to 1.2, DBH OR=1.1), an effect that was greater in women (SF=2.4) than in men (SF=2.0).
In support of the meta-analyses performed by Alzgene, we report only a nominal association of rs6265 (BDNF1) with AD risk (OR=1.2, p=0.3) . On the other hand, we report three novel risk-modifying BDNF polymorphisms that were associated with increased AD risk in the total or Northern European populations (OR=1.1, p<0 .01). It should be noted that the OR for rs6265 was similar to that reported for the associations reported for the other 3 polymorphisms. We therefore cannot rule out the possibility that rs6265 has a similar frequency to the other BDNF variants in AD patients, but that the significance of this increased frequency is attenuated by other covariates in the model, namely age-at-collection, sex, APOE ε4 or collection centre Nevertheless, since none of these associations were significant when accounting for multiple testing (lowest p=0.0008, Bonferroni cut-off = 0.0002), these findings warrant replication in large independent cohorts.
The strongest finding of this study is the interaction between BDNF variants 2-4 (rs12288512, rs113030102, rs11030119) and sex (SF=1.3 to 1.5) such that women carriers from Northern Europe were at greater risk of AD (OR=1.3 to 1.4) than men (OR=0.9 to 1.0), associations that were significant even after accounting for multiple testing in at least one dataset. The evidence for the BDNF2*sex interaction reported here is particularly strong, as it was observed in both the Northern European (increased risk in women) and Spanish (decreased in men) subsets as well as the total dataset. This is not the first study to identify sex differences related to the BDNF locus in AD, albeit that a previous study reported an association of BDNF1 (rs6265) with increased AD risk in women from the Han Chinese population [56] , a variant that did not interact with sex in this study (p=0.9). Moreover, the gender effect may not be limited to AD; a greater neuroprotective effect against methamphetamine-induced toxicity (i.e., greater preservation of corpus striatal dopamine levels) has been reported in male compared to female mice over-expressing Bdnf [57] . In another study, modulation of Bdnf expression in response to acute stress was impaired in female rats [58] . The mechanism underlying the gender difference observed in this and other studies has yet to be fully explored. However, a direct interaction between estrogen receptors and BDNF transcription has been shown to alter hippocampal physiology during development in the rat, suggesting that hormonal variation during a critical time window may contribute to sex-specific effects in BDNF transcription [59] . Whether the BDNF variants reported here also affect BDNF transcription has yet to be explored. If a functional effect is demonstrated, a hypothesis arises whereby BDNF expression may be natively lower in adult women, which, when combined with carrying a genetic variant that may also affect brain BDNF levels, could have a multiplicative effect on susceptibility to AD pathology, thereby increasing risk for AD in female carriers compared to male noncarriers. This is an intriguing avenue worth pursuing in future functional studies.
It is possible that BDNF variants could differentially influence a range of brain regions and networks. Therefore, functional studies to determine how these variants may influence noradrenergic innervation of the hippocampus, frontal cortex, and cerebellum could also be informative. Moreover, whether functional effects can be directly attributed to the polymorphisms included in the study, or rather to other polymorphisms within the linkage disequilibrium blocks that they capture, also warrants further investigation.
We also report a synergistic interaction (SF=2.2) between BDNF1 (rs6265) and DBH1
(rs1611115) that contributed more to AD risk in Northern European women (SF=2.4) than men (SF=2), an association that was not apparent for the other BDNF variants.
This result is particularly intriguing since the rs6265 variant alone showed the weakest association with AD risk. As the interaction did not survive adjustment for multiple testing (p=0.007, Bonferroni cut-off = 0.0002), validation in an independent study is necessary. If validated, this interaction could indicate a combinatorial functional effect between BDNF and DBH variants that is specific to the rs6265 polymorphism, thus highlighting the importance of considering epistatic interactions in genetic studies to unmask otherwise hidden associations with AD. We have previously reported a synergistic interaction between DBH (rs1611115) and pro-inflammatory cytokines [39, 45] that contributed to increased risk for AD. As BDNF and DBH are involved in a feed-forward anti-inflammatory mechanism, these studies could point toward a complex interaction between genes that encode proteins involved in neuroinflammatory pathways and furthermore that these interactions may differ according to sex.
A limitation of this study is the use of Alzheimer's disease diagnosis as a single endpoint, which does not account for the possibility of disease-modifying effects of these variants on brain atrophy or cognitive decline, particularly if these effects are only evident at early stages. The ORs reported in this study, although modest (1.1 to 1.6), suggest a mild effect on AD risk, as would be expected from a complex genetic disorder such as AD.
Overall, these data suggest a complex interplay between BDNF and sex that warrants further investigation in large, independent studies. 
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